Hydroxychloroquine Market Report 2026

Hydroxychloroquine Market Overview

• Hydroxychloroquine market size has reached to $2.38 billion in 2025 • Expected to grow to $3.26 billion in 2030 at a compound annual growth rate (CAGR) of 6.6% • Growth Driver: Rising Rheumatoid Arthritis Cases Boosting Hydroxychloroquine Market • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Hydroxychloroquine Market?

Hydroxychloroquine refers to a quinolone-derived medication that is used to treat malaria. In countries or regions where it is recognized that other medications (such as chloroquine) may not be effective, it is also used to prevent malaria infection. In some hospitalized individuals, hydroxychloroquine may also be used to treat COVID-19 (COVID-19). The main types of drug activities in hydroxychloroquine are anti-malarial, anti-rheumatic, lupus suppressant, anti-COVID-19, and others. Antimalarial drugs, or simply 'antimalarials,' are antiparasitic chemical agents that can be utilized to cure or prevent malaria. They are generally organically sourced. The different formulations include tablets, and injections and are used in malaria, rheumatoid arthritis, lupus erythematosus, COVID-19, and others. It is distributed through various channels such as hospital pharmacies, online pharmacies, specialty drug stores, and retail pharmacies.

What Is The Hydroxychloroquine Market Growth Forecast?

The hydroxychloroquine market size is expected to see strong growth in the next few years. It will grow to $3.26 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to research on covid-19 applications, development of new formulations and delivery methods, expansion of online pharmacy channels, increasing government health initiatives for malaria prevention, rising investments in clinical trials and off-label studies. Major trends in the forecast period include rising use of hydroxychloroquine for malaria prevention and treatment, increasing adoption in rheumatoid arthritis and lupus management, growth in off-label uses and clinical research for covid-19, expansion of tablet formulations and injectable variants, rising distribution through hospital, online, and retail pharmacies.

Global Hydroxychloroquine Market Segmentation

1) By Drug Activity: Anti-Malarial Drug, Anti-Rheumatic Drug, Lupus Suppressant Drug, Anti COVID-19 Drug, Other Drug Activity 2) By Formulation: Tablets, Injection 3) By Application: Malaria, Rheumatoid Arthritis, Lupus Erythematosus, COVID-19, Other Applications 4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Specialty Drug Stores, Retail Pharmacy Subsegments: 1) By Anti-Malarial Drug: Treatment Of Malaria, Prophylaxis For Malaria 2) By Anti-Rheumatic Drug: Treatment Of Rheumatoid Arthritis, Treatment Of Juvenile Idiopathic Arthritis 3) By Lupus Suppressant Drug: Treatment Of Systemic Lupus Erythematosus 4) By Anti COVID-19 Drug: Treatment Of COVID-19 Symptoms 5) By Other Drug Activity: Treatment Of Other Autoimmune Disorders, Additional Off-label uses

What Are The Drivers Of The Hydroxychloroquine Market?

The growing cases of rheumatoid arthritis are expected to propel the growth of the hydroxychloroquine market going forward. Rheumatoid arthritis refers to an autoimmune and inflammatory condition where the immune system knowingly harms healthy cells in the body, leading to inflammation in the body areas affected. Hydroxychloroquine is beneficial for rheumatoid arthritis treatment as it can help reduce inflammation and alleviate symptoms, improving the overall quality of life for many patients. For instance, in June 2023, according to the Centers for Disease Control and Prevention, a US-based health protection agency, in the United States, there were 54.4 million adult-aged people diagnosed with arthritis, which is projected to reach 78 million by the year 2040. Therefore, the growing cases of rheumatoid arthritis are expected to drive the hydroxychloroquine industry. The rising healthcare expenditure is expected to propel the growth of the hydroxychloroquine market going forward. Healthcare expenditure refers to the total amount of resources, typically measured in monetary terms, that a country, organization, or individual allocates to health services and products. The increase in healthcare expenditure is driven by several factors, including an aging population, the prevalence of chronic diseases, advancements in medical technology, and rising consumer expectations for quality care. Hydroxychloroquine may alleviate rising healthcare costs by offering an affordable treatment alternative for multiple conditions, which can decrease the reliance on pricier medical interventions. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based non-profit organization, total health expenditure is projected to reach $344 billion in 2023, reflecting a modest growth of 2.8% compared to the previous year. Therefore, the rising healthcare expenditure is driving the growth of the hydroxychloroquine industry.

Key Players In The Global Hydroxychloroquine Market

Major companies operating in the hydroxychloroquine market are Bayer AG, Dr. Reddy's Laboratories Ltd., Zydus Group, Ipca Laboratories Ltd., Wallace Pharma, Teva Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Novartis AG, Intas Pharmaceuticals Ltd., Lupin Limited, Shanghai Zhongxi Sanwei Pharmaceutical Co. Ltd., Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals plc, Sandoz International GmbH, Cipla Limited, Shenhua Pharmaceutical Co. Ltd., Sanofi S.A., Macleod Pharmaceuticals Ltd., Laurus Labs, TAJ Pharmaceuticals, Wuhan Wuyao Pharmaceutical Co. Ltd., Concordia Healthcare, Pfizer Inc., Cadila Pharmaceuticals, Hetero Drugs Ltd., Jubilant Generics Limited, Alembic Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma USA Inc., Alkem Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Unichem Laboratories Ltd., Wockhardt Limited, Emcure Pharmaceuticals Ltd., Strides Pharma Science Ltd., Indoco Remedies Ltd.

What Are Latest Mergers And Acquisitions In The Hydroxychloroquine Market?

In August 2023, Ipca Laboratories, an India-based pharmaceutical company, acquired Unichem $0.118 billion. With this acquisition, Ipca aims to enhance its product portfolio and expand its market presence, leveraging Unichem's strengths in various therapeutic areas and boosting its capabilities in research and development. Unichem is an India-based pharmaceutical company that focuses on developing, manufacturing, and marketing a wide range of generic and branded medications across various therapeutic areas.

Regional Insights

North America was the largest region in the hydroxychloroquine market in 2025. Middle East is expected to be the fastest-growing region in the hydroxychloroquine market report. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hydroxychloroquine Market?

The hydroxychloroquine market consists of sales of plaquenil, antimalarials, and immunosuppressants. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hydroxychloroquine Market Report 2026?

The hydroxychloroquine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hydroxychloroquine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.